Ocugen stock is on the rise after sharing a pre-impression on the effectiveness of the COVID-19 vaccine against a lesser-known Brazilian variant

0
8
Ocugen stock is on the rise after sharing a pre-impression on the effectiveness of the COVID-19 vaccine against a lesser-known Brazilian variant


Actions d’Ocugen Inc. OCGN,
+ 23,99%
rose 20.2% on Monday after the Pennslyvania company said a COVID-19 vaccine it was under contract to develop with Indian biotech company Bharat Biotech International Ltd. is “potentially” effective against B.1.1.28.2, or P.2., a variant first identified in Brazil in April 2020. The variant has been designated variant of interest in the United States but is not considered as a more serious variant of concern like B.1.1.7. outside the UK or P.1, which was also first identified in Brazil, according to the Centers for Disease Control and Prevention. The study cited by Ocugen is a pre-impression, which is preliminary medical research that has not been peer-reviewed, and it compared the titers of IgG antibodies in people who had received the injections to those who had received the injections. have recovered from COVID-19. The study was conducted in a laboratory and included 61 serum samples, two of which had the B.1.1.28.2 variant. Ocugen said he was developing Bharat’s vaccine, which was approved in India in January, for the United States, but has yet to launch clinical trials for this market. The Ocugen stock has climbed 729.8% year-to-date, while the S&P 500 SPX,
+ 0,38%
is up 11.3%.

LEAVE A REPLY

Please enter your comment!
Please enter your name here